The FDA delivered a pair of holiday season approvals, signing off on Agios’ Aqvesme for the treatment of anemia in adults with alpha- or beta-thalassemia, and then issuing its final new drug approval of the year to Vanda Pharmaceuticals for
read moreAfter several months of running the direct-to-consumer “Soft Landing” campaign for its Exparel pain medication via TV, web and social media spots, Pacira BioSciences has taken the marketing initiative from digital to IRL. More: Pacira brings Exparel DTC campaign to
read moreForesee Pharmaceuticals Camcevi, currently approved as a treatment for advanced prostate cancer, showed promise in a phase 3 study that enrolled children with central precocious puberty (CPP). More: Foresee Pharmaceuticals spots prostate cancer med's potential in rare puberty disease, touts
read moreThe emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated non-small cell lung cancer following an interim data analysis. More: Verastem
read moreAlthough it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum last year, the German drugmaker ended 2025 with a glimmer of hope for the asset, thanks to multiple analyses of a
read more© 1994 - 2026 B.M. Pharmaceuticals